New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 13, 2012
10:12 EDTRFMD, HBC, DRC, CRL, LLY, VRA, MCHP, GLF, BBEP, RDY, YUM, TSO, MTB, FRME, AVGO, ENOC, BGSOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Avago (AVGO) upgraded to Buy from Neutral at Goldman... BreitBurn Energy (BBEP) upgraded to Neutral from Underperform at Credit Suisse... Charles River Labs (CRL) upgraded to Outperform from Market Perform at Wells Fargo... Dresser-Rand (DRC) upgraded to Positive from Neutral at Susquehanna... First Merchants (FRME) upgraded to Outperform from Market Perform at Keefe Bruyette... GulfMark Offshore (GLF) upgraded to Outperform from Market Perform at Wells Fargo... HSBC (HBC) upgraded to Buy from Hold at Deutsche Bank... M&T Bank (MTB) upgraded to Outperform from Market Perform at Keefe Bruyette... Microchip (MCHP) upgraded to Neutral from Sell at Goldman... RF Micro Devices (RFMD) upgraded to Overweight from Equal Weight at Barclays... Tesoro (TSO) upgraded to Outperform from Neutral at Credit Suisse... Vera Bradley (VRA) upgraded to Buy from Hold at Jefferies... B&G Foods (BGS) upgraded to Outperform from Sector Perform at RBC Capital... Yum! Brands (YUM) upgraded to Buy from Neutral at Goldman... Charles River Labs (CRL) upgraded to Overweight from Neutral at JPMorgan... Eli Lilly (LLY) upgraded to Neutral from Underperform at Cowen... EnerNOC (ENOC) upgraded to Outperform from Market Perform at Raymond James... Dr. Reddy's Labs (RDY) upgraded to Outperform from Neutral at Credit Suisse.
News For AVGO;BBEP;DRC;FRME;GLF;HBC;MTB;MCHP;RFMD;TSO;VRA;BGS;YUM;LLY;ENOC;RDY;CRL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 24, 2014
05:16 EDTRDYDr. Reddy's Labs launches Docetaxel Injection USP
Subscribe for More Information
November 20, 2014
16:16 EDTYUMYum! Brands authorizes up to $1B in share repurchases
Yum! Brands board authorized the company to repurchase up to $1B in additional shares of common stock. The $1B in additional share repurchases of the company’s outstanding common stock is authorized through May 31, 2016.
11:19 EDTDRCDresser-Rand announces investor approval of merger agreement with Siemens
Subscribe for More Information
10:02 EDTYUMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:17 EDTRDYDr. Reddy's Labs launches OTC generic Allegra-D 12-Hour
Subscribe for More Information
07:26 EDTYUMYum! Brands upgraded to Buy at Janney Capital
Subscribe for More Information
06:06 EDTYUMYum! Brands upgraded to Buy from Neutral at Janney Capital
Subscribe for More Information
November 19, 2014
16:35 EDTTSOTesoro's Chair of the Board Steven Grapstein to step down at year-end
Subscribe for More Information
November 18, 2014
16:07 EDTBBEPQR Energy shareholders approve merger with BreitBurn Energy
Subscribe for More Information
09:07 EDTBBEPQR Energy to host special shareholder meeting
Subscribe for More Information
07:20 EDTCRLEuro Organization for Research & Treatment of Cancer co-hosts a symposium
Subscribe for More Information
06:31 EDTTSOTesoro coverage resumed with a Conviction Buy at Goldman
Subscribe for More Information
November 17, 2014
16:04 EDTLLYEli Lilly says empagliflozin tablets reduced A1C, body weight and abdominal fat
Empagliflozin tablets reduced hemoglobin A1C (a measure of average blood sugar over the past two to three months), body weight and several markers of abdominal fat in adults with type 2 diabetes, according to a new retrospective analysis of clinical trial data presented on behalf of Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company at the 2014 Scientific Sessions of the American Heart Association in Chicago. Abdominal fat, also known as visceral fat, sits on or near vital organs. The study presented at AHA included analyses of two sets of adults with T2D treated with either empagliflozin or placebo. The first group consisted of 823 adults with high blood pressure who were treated for 12 weeks, while the second examined a pool of 2,476 adults from four different trials who were treated for 24 weeks. These randomized studies compared empagliflozin with placebo as an add-on to existing therapy, including metformin, metformin plus sulfonylurea, or pioglitazone with or without metformin. In both groups, treatment with empagliflozin significantly reduced A1C, body weight and several markers of abdominal fat compared with placebo. Changes in estimated total body fat did not reach statistical significance.
11:06 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:16 EDTRFMDRF Micro Devices and TriQuint recommended at Craig-Hallum
Craig-Hallum recommends RF Micro Devices (RFMD) and TriQuint (TQNT) and believes the combined company will imply EPS in the $1.40 range. The analyst said the RF Semi space has some of the best growth in tech and reiterates its Buy ratings for both companies.
08:48 EDTRFMD, AVGOSkyworks, Avago, and RF Micro Devices recommended at BofA/Merrill
Subscribe for More Information
November 14, 2014
14:53 EDTLLYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
13:30 EDTBGSB&G Foods issues recall, allergy alert on undeclared nuts in certain products
B&G Foods announced it is voluntarily recalling certain Ortega Taco Seasoning Mix, Ortega Taco Sauce, Ortega Enchilada Sauce and Ortega Taco Kit products and certain Las Palmas Taco Seasoning Mix and Las Palmas Taco Sauce products after learning that one or more of the spice ingredients purchased from a third party supplier contain peanuts and almonds, allergens that are not declared on the products’ ingredient statements. People who have an allergy or severe sensitivity to peanuts and almonds run the risk of serious or life-threatening allergic reaction if they consume these products. There is no health risk associated with these products for individuals without an allergy to peanuts or almonds. This recall was initiated in consultation with the FDA after it was discovered that ingredients from a single supplier used in the affected products were contaminated with peanut and almond allergens. B&G Foods has since terminated its relationship with this supplier and is receiving these ingredients from other sources in anticipation of resuming production shortly.
13:25 EDTBGSB&G Foods trading halted, pending news
Subscribe for More Information
08:48 EDTRFMDRF Micro should be bought on any merger related weakness, says Pacific Crest
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use